Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Interest Expenses (2017 - 2022)

Historic Interest Expenses for Sutro Biopharma (STRO) over the last 6 years, with Q3 2022 value amounting to $2.8 million.

  • Sutro Biopharma's Interest Expenses rose 24000.0% to $2.8 million in Q3 2022 from the same period last year, while for Jun 2023 it was $2.8 million, marking a year-over-year increase of 391.35%. This contributed to the annual value of $3.1 million for FY2021, which is 2305.62% down from last year.
  • Sutro Biopharma's Interest Expenses amounted to $2.8 million in Q3 2022, which was up 24000.0% from $594000.0 recorded in Q2 2022.
  • Sutro Biopharma's 5-year Interest Expenses high stood at $3.0 million for Q2 2020, and its period low was -$2.3 million during Q4 2020.
  • For the 5-year period, Sutro Biopharma's Interest Expenses averaged around $805947.4, with its median value being $820000.0 (2021).
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 34299.8% in 2019, then crashed by 37552.02% in 2020.
  • Over the past 5 years, Sutro Biopharma's Interest Expenses (Quarter) stood at -$649000.0 in 2018, then soared by 225.89% to $817000.0 in 2019, then plummeted by 375.52% to -$2.3 million in 2020, then skyrocketed by 127.19% to $612000.0 in 2021, then skyrocketed by 355.56% to $2.8 million in 2022.
  • Its Interest Expenses stands at $2.8 million for Q3 2022, versus $594000.0 for Q2 2022 and $657000.0 for Q1 2022.